Skip to content
10-Q

Quarterly Report

AMICUS THERAPEUTICS, INC.

0001178879-25-000006

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 24, 2025 307.93M sh
Shares Diluted Q1 2025 · Mar 31, 2025 307.69M sh
Shares Diluted Q1 2025 · Mar 31, 2024 302.9M sh
Capex Q1 2025 · Mar 31, 2025 $212K
Capex Q1 2025 · Mar 31, 2024 $1.81M
Operating Cash Flow Q1 2025 · Mar 31, 2025 $7.76M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$29.7M
Long Term Debt Q1 2025 · Mar 31, 2025 $390.71M
Long Term Debt Q1 2025 · Dec 31, 2024 $390.11M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $181.66M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $213.75M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $209.76M
Stockholders Equity Q1 2025 · Mar 31, 2025 $193.56M
Stockholders Equity Q1 2025 · Dec 31, 2024 $194.05M
Stockholders Equity Q1 2025 · Mar 31, 2024 $130.69M
Stockholders Equity Q1 2025 · Dec 31, 2023 $160.17M
Current Liabilities Q1 2025 · Mar 31, 2025 $152.89M
Current Liabilities Q1 2025 · Dec 31, 2024 $148.7M
Total Liabilities Q1 2025 · Mar 31, 2025 $596.28M
Total Liabilities Q1 2025 · Dec 31, 2024 $590.99M
Current Assets Q1 2025 · Mar 31, 2025 $510.8M
Current Assets Q1 2025 · Dec 31, 2024 $504.74M
Total Assets Q1 2025 · Mar 31, 2025 $789.84M
Total Assets Q1 2025 · Dec 31, 2024 $785.03M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.07
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.16
Eps Basic Q1 2025 · Mar 31, 2025 −$0.07
Eps Basic Q1 2025 · Mar 31, 2024 −$0.16
Sga Expense Q1 2025 · Mar 31, 2025 $91.83M
Sga Expense Q1 2025 · Mar 31, 2024 $88.03M
Net Income Q1 2025 · Mar 31, 2025 −$21.69M
Net Income Q1 2025 · Mar 31, 2024 −$48.42M
Operating Income Q1 2025 · Mar 31, 2025 −$7.95M
Operating Income Q1 2025 · Mar 31, 2024 −$27.72M
Gross Profit Q1 2025 · Mar 31, 2025 $113.55M
Gross Profit Q1 2025 · Mar 31, 2024 $96.84M
Revenue Q1 2025 · Mar 31, 2025 $125.25M
Revenue Q1 2025 · Mar 31, 2024 $110.4M